Published in Klin Wochenschr on August 15, 1975
Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell (1997) 7.47
Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci U S A (1985) 3.02
Retracted Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med (1995) 2.97
Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes. J Exp Med (1984) 2.26
Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood (1996) 2.08
Leg ulceration with associated thrombocytosis: healing of ulceration associated with treatment of the raised platelet count. Br J Dermatol (1998) 2.08
Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood (1994) 1.95
Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulation of transferrin receptor expression. J Immunol (1985) 1.86
Expression of bcl-2 in Burkitt's lymphoma cell lines: induction by latent Epstein-Barr virus genes. Blood (1992) 1.81
High-level secretion of tumor necrosis factor-alpha contributes to hematopoietic failure in hairy cell leukemia. Blood (1989) 1.64
Effects of aerobic exercise on the physical performance and incidence of treatment-related complications after high-dose chemotherapy. Blood (1997) 1.61
Stimulation of immunoglobulin secretion in human B lymphocytes as a direct effect of high concentrations of IL 2. J Immunol (1984) 1.54
Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity. J Exp Med (1982) 1.50
Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation. Cancer (1997) 1.41
An aerobic exercise program for patients with haematological malignancies after bone marrow transplantation. Bone Marrow Transplant (1996) 1.38
Biological activities of a human pluripotent hemopoietic colony stimulating factor on normal and leukemic cells. J Exp Med (1985) 1.37
Retracted Granulocyte-macrophage colony-stimulating factor induces cytokine secretion by human polymorphonuclear leukocytes. J Clin Invest (1989) 1.37
The function of 80 S ribosomal subunits and effects of some antibiotics. Cold Spring Harb Symp Quant Biol (1969) 1.35
Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood (1989) 1.33
Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood (1998) 1.32
Tumor necrosis factor (TNF)-alpha but not TNF-beta induces secretion of colony stimulating factor for macrophages (CSF-1) by human monocytes. Blood (1987) 1.31
IL-10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, and Stat5) and their distinct combinatorial assembly in the promoters of selected genes. FEBS Lett (1996) 1.29
Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays. Anticancer Drugs (1995) 1.29
Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer. Eur J Cancer (1996) 1.26
Regulatory role of a monomorphic determinant of HLA Class I antigens in T cell proliferation. J Immunol (1985) 1.23
Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol Immunother (2000) 1.22
T-cell activation defect in common variable immunodeficiency: restoration by phorbol myristate acetate (PMA) or allogeneic macrophages. Clin Immunol Immunopathol (1987) 1.19
OKT8 antibody inhibits OKT3-induced IL 2 production and proliferation in OKT8+ cells. J Immunol (1983) 1.19
Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood (1980) 1.18
Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie (2003) 1.17
BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases. J Clin Oncol (1996) 1.17
Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res (1990) 1.16
Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndrome. J Clin Invest (1985) 1.15
Pluripoietin alpha: a second human hematopoietic colony-stimulating factor produced by the human bladder carcinoma cell line 5637. Proc Natl Acad Sci U S A (1986) 1.14
Production and regulation of interleukin-2 in human lymphoblastic leukemias studied with T-cell monoclonal antibodies. Blood (1983) 1.11
Human pluripotent hemopoietic colony stimulating factor: activities on human and murine cells. Immunobiology (1986) 1.09
Generation of nonspecific murine cytotoxic T cells in vitro by purified human interleukin 2. Cell Immunol (1984) 1.07
N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. Blood (1990) 1.07
Interleukin-10 increases Bcl-2 expression and survival in primary human CD34+ hematopoietic progenitor cells. Blood (1996) 1.07
Immunologic effects of interleukin 2 in primary immunodeficiency diseases. J Immunol (1983) 1.06
Correlation between physical performance and fatigue in cancer patients. Ann Oncol (1997) 1.05
Autologous and allogeneic mixed-lymphocyte responses following thermal injury in man: the immunomodulatory effects of interleukin 1, interleukin 2, and a prostaglandin inhibitor, WY-18251. Clin Immunol Immunopathol (1984) 1.04
Interleukin-4 induces secretion of CSF for granulocytes and CSF for macrophages by peripheral blood monocytes. Blood (1989) 1.01
Human interleukin 2: molecular biology, physiology and clinical possibilities. Immunobiology (1986) 1.00
BCL-2 induction is part of the strategy of Epstein-Barr virus. Leuk Lymphoma (1994) 1.00
Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol Immunother (1999) 0.99
The acute monocytic leukemias: multidisciplinary studies in 45 patients. Medicine (Baltimore) (1980) 0.99
The JAK-STAT pathway: signal transduction involved in proliferation, differentiation and transformation. Leuk Lymphoma (1998) 0.99
Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro. Int J Cancer (1991) 0.98
Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood (1990) 0.97
Downregulation of the proinflammatory cytokine response to endotoxin by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients. Blood (1997) 0.97
Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study. Ann Hematol (2003) 0.97
Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. Ann Oncol (1995) 0.97
Protein synthesis in human leucocytes. IV. Mutual inhibition of amino acid incorporation by amino acids in cell suspensions and cell-free systems. Hoppe Seylers Z Physiol Chem (1972) 0.96
Expansion of cyclophosphamide-resistant cytotoxic precursors in vitro and in vivo by purified human interleukin 2. J Immunol (1983) 0.96
Leukotriene B4 transcriptionally activates interleukin-6 expression involving NK-chi B and NF-IL6. Eur J Immunol (1992) 0.96
High concentrations of the interleukin-1 receptor antagonist in serum of patients with Hodgkin's disease. Lancet (1992) 0.95
Characterization of malignant lymphomas in leukemic phase by multiple differentiation markers of mononuclear cells. Correlations with clinical features and conventional morphology. Am J Med (1977) 0.95
Aspergillus Peritonitis complicating perforated appendicitis in adult acute leukemia. J Surg Oncol (1982) 0.94
Treatment of immunodeficiency with interleukin-2: initial exploration. J Biol Response Mod (1984) 0.93
Abnormally high concentrations of beta 2 microglobulin in acquired immunodeficiency syndrome (AIDS) patients. Clin Chem (1983) 0.93
Neutrophilic leukemia accompanied by hemorrhagic diathesis: report of two cases. Blut (1987) 0.93
Specific interactions of ribosomes in decoding. Cold Spring Harb Symp Quant Biol (1966) 0.93
Isolation and purification of DNA-dependent RNA polymerase from nuclei of human placenta. (Nucleoside triphosphate: ribonucleic acid nucleotidyl transferase, e.c.2.7.7.6.). Biochem Biophys Res Commun (1968) 0.92
Interleukin 2-dependent natural killer (NK) cell lines from patients with primary T cell immunodeficiencies. J Immunol (1983) 0.91
Retracted Mithramycin selectively inhibits collagen-alpha 1(I) gene expression in human fibroblast. J Clin Invest (1993) 0.91
ADP-ribosylation of nuclear proteins in normal lymphocytes and in low-grade malignant non-Hodgkin lymphoma cells. Eur J Biochem (1980) 0.90
A switch toward demethylation is associated with the expression of myeloperoxidase in acute myeloblastic and promyelocytic leukemias. Blood (1992) 0.90
Natural inhibitors of T-cell activation in Hodgkin's disease. Blood (1991) 0.89
Lymphoblastic lymphoma in adults. J Clin Oncol (1986) 0.89
The transjugular stent implantation for the treatment of malignant portal and hepatic vein obstruction in cancer patients. Ann Oncol (1997) 0.88
Common variable immunodeficiency syndrome and nodular lymphoid hyperplasia in the small intestine. Endoscopy (1988) 0.88
Specific translocations characterize Burkitt's-like lymphoma of homosexual men with the acquired immunodeficiency syndrome. Blood (1983) 0.87
Clonal analysis of bcr-abl rearrangement in T lymphocytes from patients with chronic myelogenous leukemia. Blood (1992) 0.87
Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol (1990) 0.87
Images in cardiovascular medicine. Metabolic imaging identifies non-Hodgkin's lymphoma infiltrating heart. Circulation (1998) 0.87
Induction of differentiation in human marrow T cell precursors by the synthetic serum thymic factor, FTS. Clin Exp Immunol (1980) 0.87
Granulocyte-macrophage colony-stimulating factor and interleukin-3 induce surface expression of interleukin-2 receptor p55-chain and CD4 by human eosinophils. Immunology (1990) 0.86
CD34+ peripheral blood progenitor cell and monocyte derived dendritic cells: a comparative analysis. Br J Haematol (1997) 0.86
Interleukin-2 and interferon-gamma recruit different subsets of human peripheral blood monocytes to secrete interleukin-1 beta and tumour necrosis factor-alpha. Clin Exp Immunol (1989) 0.86
Systemic infection with Trichosporon cutaneum in a patient with acute leukemia: report of a case. Cancer (1981) 0.86
Granulocyte-macrophage colony-stimulating factor (CSF) and multilineage CSF recruit human monocytes to express granulocyte CSF. Blood (1989) 0.85
Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin. Br J Haematol (2000) 0.85
Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols. J Clin Oncol (1983) 0.85
Adhesion and migration are differentially regulated in hematopoietic progenitor cells by cytokines and extracellular matrix. Blood (1997) 0.85
Lymphoblastic neoplasia in a homosexual patient with Kaposi's sarcoma. Ann Intern Med (1983) 0.85
The suppressive effects of recombinant human tumor necrosis factor-alpha on normal and malignant myelopoiesis: synergism with interferon-gamma. Int J Cell Cloning (1988) 0.85
Maintenance of transplantation potential in ex vivo expanded CD34(+)-selected human peripheral blood progenitor cells. Blood (1994) 0.85
Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy. Am J Med (1990) 0.84
Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy. Eur J Cancer (1991) 0.84
Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia. Cancer Res (1985) 0.84
Mechanisms contributing to the virus persistence in Aleutian disease. Dtsch Tierarztl Wochenschr (1990) 0.84
Regulation of gene expression of M-, G-, GM-, and multi-CSF in normal and malignant hematopoietic cells. Blood Cells (1988) 0.84
Control of globin synthesis during DMSO-induced differentiation of mouse erythroleukemic cells in culture. Hamatol Bluttransfus (1974) 0.84